The new integrated drug discovery alliance’s goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years.
The collaboration leverages Evotec’s hit identification platform including the screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s drug development and advancing science in dermatology. Evotec’s integrated discovery scientists will work in a joint team with scientists from LEO Pharma. The alliance will receive further support with high-value drug development and discovery ADME-Tox services.
“Innovation through partnerships plays a key role in LEO Pharma’s approach to developing new medicines. We are confident that our alliance with Evotec will further strengthen our research and help us expedite the discovery of novel small molecule therapeutics for skin diseases, for which there are large unmet medical needs, thus helping even more patients in the future,” says Dr Thorsten Thormann, Vice President, Research at LEO Pharma.
No financial details of this fee-for-service collaboration were disclosed.